Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences Inc (NASDAQ: PLSE) pioneers bioelectric medicine through its proprietary Nano-Pulse Stimulation technology, offering investors and medical professionals a novel approach to non-thermal therapies. This dedicated news hub provides real-time updates on clinical advancements, regulatory developments, and strategic partnerships shaping the future of targeted cellular treatments.
Access verified information about PLSE's progress in immuno-oncology applications, dermatology research breakthroughs, and system commercialization efforts. Our curated feed includes earnings reports, FDA submissions, peer-reviewed study results, and executive commentary – all essential for evaluating the company's position in the electroceuticals market.
Key updates cover therapeutic trial milestones, intellectual property expansions, and collaborations with leading medical institutions. Bookmark this page to monitor how PLSE's drug-free energy modalities could transform treatment protocols for complex conditions while driving long-term value in the medical device sector.
Pulse Biosciences (NASDAQ: PLSE) has received FDA Investigational Device Exemption (IDE) approval to begin its NANOCLAMP AF study for treating atrial fibrillation using their novel Nanosecond Pulsed Field Ablation (nsPFA) Cardiac Surgery System. The study will enroll up to 136 patients across 20 sites, including two international locations.
The company's nsPFA technology represents a breakthrough in cardiac ablation, offering a nonthermal approach that may provide significant advantages over traditional thermal methods like radiofrequency ablation. Early clinical data from the ongoing EU feasibility study, which has treated over 40 patients, shows promising results with rapid ablation times as fast as 2.5 seconds.
The nsPFA Cardiac Surgical System previously received FDA Breakthrough Device Designation in July 2024 and is part of the FDA's Total Product Life Cycle Advisory Program.
Pulse Biosciences (Nasdaq: PLSE), a nanosecond Pulsed Field Ablation technology company, has granted equity inducement awards to two new employees. The Compensation Committee approved stock options to purchase 3,950 shares of common stock at an exercise price of $16.16 per share, equal to the closing price on August 15, 2025.
The options will vest over four years with 25% vesting annually, contingent on continued employment. These grants were made outside the Company's 2017 Equity Incentive Plan but under the 2017 Inducement Equity Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
Pulse Biosciences (Nasdaq: PLSE) has announced the first successful procedures in its PRECISE-BTN clinical study, evaluating the company's nsPFA™ Percutaneous Electrode System for treating benign thyroid nodules (BTNs).
The multicenter IRB-approved study will include up to 50 patients across four sites, with follow-up evaluations at 1, 3, 6, and 12 months post-procedure. The study aims to demonstrate the safety and efficacy of this organ-sparing technology in reducing BTN symptoms while preserving thyroid function.
Dr. Ralph P. Tufano, principal investigator at Sarasota Memorial Hospital, reported early positive results from the first two procedures. The study will assess endpoints including safety, nodule volume reduction, symptom improvement, and quality of life impacts.
Pulse Biosciences (Nasdaq: PLSE) announced the publication of first-in-human clinical feasibility study results in the Journal Thyroid, demonstrating the effectiveness of their Nanosecond Pulsed Field Ablation (nsPFA) technology for treating benign thyroid nodules.
The study, conducted at Ospedale del Mare in Naples, Italy, showed remarkable results with the CellFX nsPFA Percutaneous Electrode System. Fully treated nodules achieved up to 93% reduction in size at 1 year (86% average), with >48% reduction as early as 2 weeks. The technology demonstrated 71% nodule reduction within one month, significantly outpacing traditional RFA treatments which typically require six months for comparable results.
The nsPFA technology's nonthermal mechanism uniquely preserves surrounding nerves and blood vessels, enabling safe treatment near critical anatomical structures while avoiding internodular fibrosis and scarring.
Pulse Biosciences (Nasdaq: PLSE) reported significant progress across its three key market development programs utilizing its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology. The company has treated over 140 Benign Thyroid Nodule patients and submitted FDA IDE applications for both cardiac surgical clamp and nsPFA 360° catheter programs.
In cardiac applications, PLSE has treated 40 patients in their surgical AF ablation program and over 140 patients with the nsPFA 360° catheter in Europe, showing positive clinical outcomes. Financial results show Q2 2025 GAAP net loss of $19.2 million, with cash reserves of $106.3 million as of June 30, 2025.
Pulse Biosciences (Nasdaq: PLSE), a pioneer in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced its participation in the 45th Canaccord Genuity Annual Growth Conference in Boston. The company's management team will deliver a presentation on August 13, 2025, at 11:00 am ET.
Investors can access both live and recorded versions of the presentation through the company's investor relations website under the "Events Calendar and Presentations" section at investors.pulsebiosciences.com.
Pulse Biosciences (Nasdaq: PLSE), a company focused on Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has scheduled its Q2 2025 business updates and financial results conference call for August 12, 2025, after market close.
The conference call will begin at 1:30 PM PT / 4:30 PM ET. Investors can join via phone using the numbers 1-800-715-9871 or 1-646-307-1963 with passcode 2036874. A live and recorded webcast will be available on the company's investor relations website.
Pulse Biosciences (Nasdaq: PLSE), a nanosecond Pulsed Field Ablation technology company, has granted equity inducement awards to its new principal accounting officer and four other new employees. The Compensation Committee approved a total of 68,217 stock options under the 2017 Inducement Equity Incentive Plan on July 14, 2025.
Steven T. Weber, the new principal accounting officer, received 55,000 options split equally between time-based vesting over four years and performance-based objectives tied to market capitalization goals ranging from $1.5 billion to $4.0 billion. The remaining employees received time-based vesting options over four years. All options have an exercise price of $16.03 per share.
Pulse Biosciences (PLSE), a company specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has granted equity inducement awards to four new employees. The awards, approved on May 19, 2025, consist of stock options to purchase a total of 8,300 shares of company common stock at an exercise price of $17.13 per share, equal to the closing price on the grant date.
The options were granted outside the Company's 2017 Equity Incentive Plan but under the 2017 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards feature a four-year time-based vesting schedule, with 25% vesting annually, contingent on continued employment.
FAQ
What is the current stock price of Pulse Biosciences (PLSE)?
What is the market cap of Pulse Biosciences (PLSE)?
